Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 6/6/human leukocyte antigen (HLA) matched sibling donor or related donor, or acceptable matched unrelated donor~* Biopsy (Bx) proven diagnosis of LG (including small lymphocytic lymphoma \[SLL\]/chronic lymphocytic leukemia \[CLL\], lymphoplasmacytic lymphoma, marginal zone, mucosa-associated lymphoid tissue \[MALT\] lymphoma and follicular lymphoma \[FL\] grade 1 and 2), IG (FL grade 3 and DLCL) or MCL NHL~* Prior demonstrated monoclonal CD20+ malignant B-Cell population in lymph nodes and/or BM Bx specimen~* LG NHL; must have relapsed after achieving a complete response (CR) or partial response (PR) to prior therapy or have never responded to prior therapy, including chemotherapy and/or MAb therapy~* MCL NHL in any disease state~* Other aggressive B-cell lymphomas (excluding Burkitt lymphoma or Burkitt-like lymphoma) having had at least one relapse or having been refractory to chemotherapy~* Bone marrow (BM) aspiration and Bx ( =\< 42 days prior to imaging dose) which show \< 25% lymphomatous involvement of total cellularity; in CLL, peripheral lymphocyte count \< 5000/mm\^3~* Salvage chemotherapy/MAbs to reduce BM lymphomatous involvement and reduce disease bulk allowed~* Normal renal function test with serum creatinine of =\< 1.5 mg/dl, or a creatinine clearance of \>= 60 ml/min~* Adequate pulmonary function as measured by forced expiratory volume in one second (FEV1) \> 65% of predicted measured, or a diffusing capacity of carbon monoxide (DLCO) \>= 50% of predicted measured~* Cardiac Ejection fraction of \> 50% by Echocardiogram (ECHO) or multi gated acquisition (MUGA)~* Adequate liver function tests with a bilirubin of =\< 1.5 x normal and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) =\< 2 x normal~* Negative Human Immunodeficiency Virus (HIV) antibody~* Karnofsky Performance Status (KPS) \> 80~* No active Central Nervous System (CNS) disease or prior history of CNS disease~* Involved field External Beam Therapy (EBT) to area excluding lung, heat, liver, and kidney allowed, but evaluated on a case-by-case basis~* Recovery from last therapy and therapy dose (Y-90 Zevalin) must be \>= 4 weeks from prior systemic chemotherapy~* DONOR: Age \< 75 years~* DONOR: HLA genotypically identical related donor or acceptable matched unrelated donor~* DONOR: Must consent to G-CSF administration and leukapheresis for matched sibling donor, but for unrelated donor, the donor will sign a standard consent for donation at their designated donor or collection center~* DONOR: Must have adequate veins for leukapheresis or agree to placement of a Central Venous Catheter (CVC \[femoral, subclavian\])~Exclusion Criteria:~* Presence of Human Anti-Zevalin Antibody (HAZA)~* Prior radioimmunotherapy (RIT)~* Prior AHSCT; but prior aHSCT is allowed; prior fractionated total body irradiation (FTBI) in the conditioning regimen will be evaluated on an individual basis~* Prior malignancy, except for: adequately treated basal cell or squamous cell skin cancer; adequately treated noninvasive carcinomas; or other cancer from which the patient has been disease-free for at least 5 years; myelodysplastic syndromes (MDS) is excluded from this criterion~* Active evidence of Hepatitis B or C infection; hepatitis B surface antigen positive~* Total peripheral lymphocyte count \> 5,000/mm\^3 if SLL/CLL~* Burkitt lymphoma or Burkitt-like lymphoma~* DONOR: Age \< 12 years~* DONOR: Identical twin~* DONOR: Pregnancy~* DONOR: HIV infection~* DONOR: Inability to achieve adequate venous access~* DONOR: Known allergy to G-CSF~* DONOR: Current serious systemic illness or any disease that may preclude the use of G-CSF (eg, recent thromboembolic event); for unrelated donors, considered ineligible by National Marrow Donor Program (NMDP) donor evaluation center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (chemo, monoclonal antibody therapy, transplant) (Type: EXPERIMENTAL): REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.

Based on this trial design, predict the completion outcome and termination type (if applicable).